Anthony Deluise, MD
Hand Surgery · Providence, RINPI 1588605992
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (51.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Arthrex at 37.0% of the total. Reporting peaked in 2019 at $3,533 and has fallen 98.8% since, to $41 in 2025.
Across 37 payments — averaging $188.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$3K
- Depuy Synthes Products, Inc.$2K
- Kairos Surgical Inc$1K
- Stryker$1K
- Bioventus LLC$96
- Amgen$73
- plus $266 from 10 others
What the payments were for
- Consulting fees$1,57523%
- Travel & lodging$71110%
- Food & beverage$1,10216%
- Education$3,60152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 4 | $2,583 |
| Depuy Synthes Products, Inc. | 2 | $1,575 |
| Kairos Surgical Inc | 2 | $1,215 |
| Stryker | 9 | $1,180 |
| Bioventus LLC | 3 | $96 |
| Amgen | 4 | $73 |
| Ferring Pharmaceuticals Inc. | 3 | $50 |
| Davol Inc. | 1 | $41 |
| Johnson & Johnson | 1 | $39 |
| Endo Pharmaceuticals Inc. | 2 | $28 |
| Radius Health, Inc. | 1 | $25 |
| Lifenet Health | 1 | $24 |
| Illuminoss Medical, Inc. | 1 | $23 |
| Biotissue Holdings Inc. | 1 | $14 |
| Pacira Therapeutics, Inc. | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FMS$1,575
- BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION$825
- INSPACE$140
How this compares
Too few hand surgery providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Naloxone Hcl | 22 | $1,383 |
| Ibuprofen | 83 | $973 |
| Tramadol Hcl | 107 | $498 |
| Oxycodone Hcl | 107 | $470 |
| Gabapentin | 66 | $353 |
| Ondansetron Hcl | 30 | $288 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $163 |
| Meloxicam | 44 | $158 |
| Naproxen | 17 | $146 |
Paid to pharmacies, not to this prescriber.
Other hand surgery in Providence
- Arnold-Peter WeissProvidence$568K
- Edward AkelmanProvidence$24K
- Julia KatarincicProvidence$2K
- Eric WalshProvidence$565
- Joseph IzziProvidence$149
- Joseph GilEast Providence$7K
- Travis BloodWarwick$6K
- Matthew AkelmanCranston$5K
- Andrew MatsonWarwick$4K
- Manuel DasilvaE Greenwich$429
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.